Public-Private Partnerships Accomplishments

CTSA-IP

The CTSA Public-Private Partnership KFC is pleased to announce CTSA-IP, an IP aggregating web-based search engine at: http://www.ctsaip.org/.

The purpose of the website is to aggregate and market technologies from CTSA institutions as well as those of the National Institutes of Health, with the goal of enhancing research activity and private partnerships across the CTSA consortium. The website includes a text-searchable interface and regular, automatic updating with a standardized template to facilitate broad participation by CTSA consortium members. Currently, there are 15 CTSAs contributing information on their technologies to the site. CTSA institutions that wish to join should contact Mike Hazard at the University of Rochester (michael_hazard@urmc.rochester.edu).

*Important Update Regarding CTSA-IP* CTSA-IP and Flintbox Collaboration Press Release

CTSA Pharmaceutical Assets Portal

The CTSA Pharmaceutical Assets Portal "matches" researchers with investigational drugs and/or biologics that may be useful in elucidating disease mechanisms and/or new uses for clinical treatment.

New Resources for Streamlining Clinical Trial and Material Transfer Agreements

NCATS would like to bring to your attention some efforts now underway to streamline clinical trial and material transfer agreement negotiations between industry and academic research centers.

The National Cancer Institute’s Standard Terms of Agreement for Research Trial (START) Clauses focus on company-sponsored and investigator-initiated clinical trial agreements. These contain model language on key concept areas including intellectual property, study data, indemnification, subject injury, confidentiality, and publication rights. For additional information, visit http://ccct.cancer.gov.

The Institute of Medicine offers similar resources at www.iom.edu/cta-mta, including:

  • A clinical trial agreement template intended for use between an industry sponsor and an academic research center in a sponsor-initiated, Phase 2 or Phase 3 multi-center clinical trial.
  • A material transfer agreement intended for use in connection with transfers of materials other than biological materials, such as small molecule compounds, from a for-profit entity to an academic research institution for use in research that is not funded by the for-profit entity.

H. Gilbert Smith, Ph.D., Office of Corporate Collaborations, Duke University School of Medicine, who is active in NCRR’s Clinical and Translational Science Award (CTSA) Consortium, has prepared a comparison of the NCI and IOM CTA and MTA provisions.

Core Competencies for Drug Development and Device Innovation

PPP, in collaboration with Strategic Goal 2,  has produced a list of core competencies in drug development and device innovation for clinical and translational researchers. These core competencies can be viewed here.

ctsa iconToolbox
  • ctsa icon Learn Learn about the CTSA Consortium Learn More »
  • ctsa icon View View the scientific portfolio of the CTSA Consortium Learn More »
  • ctsa icon Find Find resources, tools, collaborators, and best practices Learn More »
  • ctsa icon Participate Participate in committees, events, training, and collaborations Learn More »
  • ctsa icon Plan Plan to leverage CTSA resources for multi-center studies Learn More »
  • ctsa icon Submit Submit news, science stories, questions, comments, ideas Learn More »